Cabinet Decision To Revise GCP Ordinance
This article was originally published in PharmAsia News
The Japanese government approved the Cabinet’s Policy on Regulatory Reforms July 10 and will revise ordinances to make domestic GCP content more consistent with international good clinical practice policies.
You may also be interested in...
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.